Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review
Authors
Abstract:
Pheochromocytomas (PCCs) are rare neuroendocrine tumors. The current diagnostic tools are based on biochemistry and histopathology results, but heterogeneity of diagnostic markers, signs and symptoms of PCCs bring a lot of difficulties for these two current methods. Unfortunately microscopic understanding of PCCs is not adequate for its confident prognosis and management. There are data linking specific genotypes of PCCs tumors to specific locations, typical biochemical phenotypes or future clinical behaviors. The detection of a germ-line mutation possibly can guide us to an early diagnosis, appropriate treatment, and regular surveillance with better prognosis not only for the patient but also for their family members. Moreover, the latest discoveries in gene sequencing, circulating DNA (ctDNA) and circulating tumor cells (CTCs) will support the exact molecular pathogenesis of PCCs in order to provide an important basis for future PCCs managements.
similar resources
A Review on Current Status and Future Potential of Transdermal Patches as a Promising Drug Delivery System
Transdermal patches are now widely used in topical and transdermal drug delivery systems (TDDS). Up to now, TDDS has been used in several conditions, such as smoking cessation, analgesic effect, nausea, contraception, and hormone therapy. Basically, there are two types of transdermal patches: the reservoir-type patches and the matrix-type patches. First generation TDDS were designed for deliver...
full textThe current status and future of theranostic Copper-64 radiopharmaceuticals
Copper-64 was produced in large scales and high specific activities in late 1990s’ using compact cyclotrons based by 64Ni(p,n)64Cu reaction and many radiopharmaceuticals developed since then by various groups based on interesting physicochemical and nuclear properties of the radionuclide. The unique emission of beta particles as well as positron particles offers a spectacu...
full textPharmacotherapy of deep-venous thrombosis: current status and future perspective
Anticoagulation is the main therapy for acute deep-vein thrombosis (DVT) of the limbs. Over the last five decades there has been little progress in the development of oral anticoagulant therapies. However, recently this area has been experiencing a rapidly changing situation thanks to the development of orally active small molecules that directly target either thrombin or activated factor X. Th...
full textNanomedicines for Parkinson Disease: Current Status and Future Perspective
Parkinson disease (PD) is the second most common progressive neurodegenerative disorder due to loss neurons in SubstantiaNigra pars compacta. A number of medical and surgical treatments are currently available but the beneficial effects wear off with long term use and many native therapies have severe side effects. Hence novel therapeutic strategies continue to be in the developmental demand. N...
full textHematopoietic stem cell mobilization: current status and future perspective
Autologous stem cell transplantation (ASCT), high-dose chemotherapy followed by hematopoietic stem cell rescue, is a widely used therapeutic strategy especially for some patients with hematological malignancies such as malignant lymphoma or multiple myeloma (MM). Because successful ASCT is crucial in these patients for improving overall survival [1], collection of a sufficient number of hematop...
full textMy Resources
Journal title
volume 12 issue 3
pages 313- 322
publication date 2017-07-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023